The spectacular failureofBristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo in the CheckMate 026 first-line lung cancer study raises questions about whether the right cut-off levels for the PD-L1 expression biomarker were used.
Bristol reported that the drug missed the primary progression-free-survival endpoint in the first-line CheckMate 026 study on Aug. 5, prompting a dive that had the company closing down 15.99% and competitors up
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?